|Systematic (IUPAC) name|
|Mol. mass||270.375 g/mol|
|14px (what is this?)|
The first material regarding the synthesis and effects of 5-MeO-DALT was sent from Alexander Shulgin to a researcher in May 2004, after which it was circulated online. In June 2004 5-MeO-DALT became available from internet research chemical vendors. In August 2004 the synthesis and effects of 5-MeO-DALT were published by Erowid.
Doses ranging from 12–20 mg were tested by Alexander Shulgin's research group.
There are numerous anecdotal reports of users consuming dosages far in excess of those tested by Alexander Shulgin, although there is no published literature on the toxicity of 5-MeO-DALT.
5-MeO-DALT has been known to directly contribute to the death of a popular businessman in the Cambridgeshire area.
Drug prohibition laws
It is legal in the UK because the allyl group is not an alkyl group, which the law requires for a tryptamine to be illegal.
Sveriges riksdag added 5-MeO-DALT to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of May 1, 2012, published by Medical Products Agency in their regulation LVFS 2012:6 listed as 5-MeO-DALT N-allyl-N-[2-(5-metoxi-1H-indol-3-yl)etyl]-prop-2-en-1-amin.
- , Morris, H. (11 May 2010). "The Last Interview With Alexander Shulgin". Vice Magazine. Retrieved 2011-02-24.
- "厚生労働省：平成１8年度無承認無許可医薬品等買上調査の結果について". Retrieved 2012-06-26. (Japanese)